Why the study?
The appropriate antithrombotic regimen for diabetic patients with AF and stable CAD at high atherothrombotic risk remains uncertain.
Does edoxaban monotherapy reduce adverse clinical and bleeding events compared to dual antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease?
Population
1040 patients with AF and stable CAD
Comparison
Edoxaban monotherapy vs dual antithrombotic therapy (edoxaban plus a single antiplatelet agent)
Design
Randomized trial
Follow-up
12 months
Key result
Edoxaban monotherapy reduced the primary composite outcome compared to dual therapy in both diabetic (6.3% vs 13.7%; HR 0.44) and non-diabetic (6.7% vs 16.3%; HR 0.39) patients with AF and stable CAD.
Authors
Loading...
Supports edoxaban monotherapy over dual therapy in AF with stable CAD regardless of diabetes; confirms consistent benefit without interaction in this RCT.
RCT (n=1,040)
randomized
Does edoxaban monotherapy reduce adverse clinical and bleeding events compared to dual antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease?
Edoxaban monotherapy significantly reduces the risk of a composite of adverse clinical and bleeding events compared to dual antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease, regardless of diabetes status.
Lee et al. (2026) conducted an RCT in atrial fibrillation and stable coronary artery disease (n=1,040). edoxaban monotherapy vs. dual antithrombotic therapy (edoxaban plus a single antiplatelet agent) was evaluated on composite of death from any cause, myocardial infarction, stroke, systemic embolism, unplanned urgent revascularization, and major or clinically relevant nonmajor bleeding at 12 months. Edoxaban monotherapy reduced the primary composite outcome compared to dual therapy in both diabetic (6.3% vs 13.7%; HR 0.44) and non-diabetic (6.7% vs 16.3%; HR 0.39) patients with AF and stable CAD.